Description

ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD)[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C48H87N13O13—-[1]Isenberg JS, et.al. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2008 Feb 15;75(4):875-82. |[2]Greenaway J, et.al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009 Jan;8(1):64-74. |[3]Punekar S,et.al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 2008;75(1):9-21. –442526-87-6–1054.28–99.49–N=C(N)NCCC[C@@H](C(N1CCC[C@H]1C(NCC)=O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CCC)NC([C@H]([C@H](O)C)NC([C@@H]([C@@H](C)CC)NC([C@H](C(C)C)NC(CNC(CN(C(C)=O)C)=O)=O)=O)=O)=O)=O)=O.CC(O)=O–Cancer; Inflammation/Immunology–10 mM in DMSO–Apoptosis—-Apoptosis–Peptides